2月23日，国发股份（600538）（600538）发布公告，就上海证券交易所此前关于公司2025年度业绩预告的问询函进行了详细回复。公告披露并回答了有 关公司2025年度业绩预告相关财务问题，主要分为营业收入构成、主要业务板块经营情况、客户结构以及拟计提商誉减值准备等三个部分。 此前，1月16日，国发股份发布公告，公司预计2025年度实现营业收入约3.3亿元，归母净亏损约8500万元；扣非归母净亏损8550万元左右。与2024年度相 比，公司归母净利润亏损减少900万元，同比减少亏损10%；扣非归母净亏损减少450万元左右。 业绩预亏的主要原因包括全资子公司广州高盛生物科技有限公司因市场竞争加剧，营业收入同比下降约10%，毛利率下降约3%，导致其净利润由盈利转 为亏损。 此外，制药厂因生产线维护和市场产品调整，营业收入较上年同期下降约30%，亏损同比增加。同时，公司预计计提商誉减值金额约6200万元。 公司业绩预告显示，预计2025年度实现营业收入约3.3亿元，扣除与主营业务无关的业务收入和不具备商业实质的营业收入仍为3.3亿元；归属于母公司所 有者的净利润-0.85亿元。 上交所要求公司补充说明营业收入扣 ...

北京市医保局近日发布通知，第十一批国家组织药品集采、二十六省联盟药品集采及2025年本市药品集 采中选结果，将于2月28日在本市所有公立医疗机构落地执行。高血压、糖尿病、肿瘤等多个病种患者 将受益。 3个批次集采覆盖临床多领域用药，各有侧重：第十一批国家集采共纳入55种药品，覆盖抗感染、抗过 敏、抗肿瘤、降血糖、降血压、降血脂、消炎镇痛等领域常用药品；二十六省联盟集采由北京、天津、 山西等省份联合开展，聚焦临床高频使用药品，通过跨省联盟集中采购模式降低价格，保障药品稳定供 应；本市药品集采聚焦区域就医需求，与国家、省联盟集采形成品类互补，进一步丰富临床用药选择。 医疗机构须按进价零差率销售3个批次集采中选药品。 2月24日起，本市医保药品招采子系统将统一调整中选药品价格；2月24日至27日为过渡期，医疗机构应 完成中选药品品种、价格、医保支付标准及信息系统调整调试等工作，并开始网上采购中选药品。2月 28日起，本市所有公立医疗机构全面执行中选结果及对应医保支付标准。3个批次集采采购周期分别 为：国家第十一批集采至2028年12月31日，二十六省联盟集采至2027年12月31日，本市药品集采为3 年。 来源：北 ...

Core Viewpoint - The company, Fuyuan Pharmaceutical (601089.SH), has participated in a national procurement process for drugs whose agreements have expired, with some of its products expected to be selected in the upcoming procurement results, which will positively impact its market share and future performance [1]. Group 1: Procurement Participation - On February 9, 2026, the company participated in the national organized procurement for drugs with expired agreements [1]. - The procurement results are expected to be implemented by the end of March 2026, allowing provincial medical institutions to sign contracts with manufacturers based on the selected results [1]. Group 2: Market Impact - Although the sales prices of the selected drugs are expected to decrease, the company aims to stabilize its existing market share [1]. - The company is positioned to potentially increase its market share due to its brand influence and reliable supply capabilities, which will have a positive effect on its future operating performance [1].

Core Viewpoint - The company, Fuyuan Pharmaceutical (601089.SH), participated in a national procurement process for drugs whose agreements have expired, with some of its products expected to be selected in the upcoming procurement results [1] Group 1: Procurement Details - The company attended the national organized procurement for drugs with expired agreements on February 9, 2026 [1] - The results of the procurement are expected to be implemented by the end of March 2026, with provincial medical institutions beginning to sign procurement contracts based on the selected results [1] Group 2: Market Impact - Although the sales prices of the selected drugs are expected to decrease, the company aims to stabilize its existing market share [1] - The company is positioned to potentially increase its market share due to its brand influence and reliable supply capabilities, which may positively impact its future operating performance [1]

Core Viewpoint - The Central Cyberspace Administration of China, in collaboration with the National Healthcare Security Administration, is actively addressing false and misleading information related to centralized drug procurement, taking legal actions against accounts that spread anxiety and misinformation [1] Group 1: False Information and Misinformation - Accounts have been identified that fabricate false information regarding the quality of drugs and medical supplies involved in centralized procurement, aiming to attract traffic [1] - Some accounts distort national policies and create false narratives to incite public anxiety regarding original and generic drugs, leading to the promotion of health products and high-end medical insurance [1] - There are instances where non-procurement products are deliberately associated with procurement to mislead the public, damaging the credibility of the procurement process [1]

Core Viewpoint - The enthusiasm of pharmacies to participate in drug centralized procurement needs to be improved, despite the government's push for their involvement [1][3]. Group 1: Government Initiatives - On January 22, the Ministry of Commerce and nine other departments issued an opinion to promote high-quality development in the drug retail industry, encouraging pharmacies to participate in centralized procurement [2]. - The opinion aims to enhance the bargaining power of pharmacies and improve supply chain efficiency by allowing them to procure through provincial medical procurement platforms [3]. Group 2: Challenges Faced by Pharmacies - Pharmacies face significant challenges in participating in centralized procurement, including the requirement for "zero markup" sales, which compresses profit margins and may lead to unprofitable operations [4]. - The lack of significant increases in prescriptions flowing from hospitals to pharmacies further restricts their willingness to engage in centralized procurement [4]. Group 3: Recommendations for Improvement - To enhance pharmacy participation, it is essential to improve the prescription flow mechanism and optimize the settlement methods for medical insurance funds, potentially reducing settlement periods from quarterly to monthly [4]. - The government should establish a robust prescription flow mechanism and improve communication channels among stakeholders to address supply shortages and ensure timely delivery of drugs [5].

Core Insights - The Zhangdian District government is focusing on enhancing medical insurance to improve public health and stimulate high-quality development through strategic initiatives and practical outcomes [1] Group 1: Medical Insurance Enhancements - The district has strengthened the three-tiered insurance system, steadily increasing coverage levels, with hospitalization reimbursement rates for employees remaining above 80% and for residents at 60% in tertiary medical institutions [3] - Outpatient coverage has been significantly improved, with reimbursement rates for residents reaching 65% for outpatient coordination and 60% for chronic and special diseases; the annual payment limit for employees has been raised to 4,500 yuan for active workers and 5,500 yuan for retirees [3] - The reimbursement rate for outpatient chemotherapy for retirees has been increased to 85%, and a one-stop system is set to provide medical assistance to 10,173 individuals by 2025, with funding of 22.27 million yuan allocated [3] Group 2: Mechanism Innovation and Reforms - Payment method reforms are being deepened, with a focus on a multi-faceted payment system primarily based on Diagnosis-Related Groups (DIP), which encourages medical institutions to control costs and improve quality [4] - The centralized procurement of drugs and medical supplies has resulted in an average price reduction of over 50%, significantly easing the financial burden on the public [4] - The district has implemented a digital transformation in medical insurance services, enhancing efficiency and accessibility through platforms like the "Love Shandong" app and "Zibo Medical Insurance" mini-program [4] Group 3: Future Initiatives - The district plans to focus on expanding insurance coverage, enhancing policy promotion to ensure all eligible individuals are enrolled [5] - There will be an emphasis on improving medical service management and implementing the new DIP payment reform while ensuring proper management of outpatient pharmacy services [5] - The district aims to further solidify the achievements of drug procurement at the grassroots level and increase the variety of drugs available [5]

Core Viewpoint - Sichuan province is accelerating the promotion of centralized procurement of medicines to grassroots healthcare institutions, allowing citizens to access these medicines at local pharmacies, private hospitals, or village clinics without needing to visit large hospitals [1] Group 1: Policy Implementation - The Sichuan Provincial Medical Insurance Bureau issued a notice on December 30, 2025, to further promote the "three advances" of centralized procurement of medicines into grassroots medical institutions, private medical institutions, and retail pharmacies [1] - The aim of the "three advances" is to expand the coverage of centralized procurement policies, enabling the public to enjoy the benefits of procurement reforms through more accessible channels [1] Group 2: Target Institutions - Public grassroots medical institutions, including township hospitals, community health service centers/stations, and village clinics, will participate in centralized procurement as per policy regulations [1] - The initiative encourages and guides designated private medical institutions and retail pharmacies to participate in centralized procurement and to stock a certain quantity of procured medicines [1]

Core Insights - The "14th Five-Year Plan" period has seen significant reforms in drug and medical consumables procurement in Dezhou City, leading to substantial price reductions and alleviating the financial burden on the public [1][2] Group 1: Procurement Measures - The Dezhou Medical Security Bureau has implemented centralized procurement to drive supply-side reforms in the pharmaceutical sector, resulting in a substantial return to reasonable pricing for drugs and medical consumables [1] - A total of 20 batches of drugs (890 varieties) and 22 batches of consumables (43 categories) have been executed under the centralized procurement system, ensuring the availability of high-quality and affordable products [1] Group 2: Financial Mechanisms - The establishment of an optimized settlement mechanism has significantly shortened the payment cycle for pharmaceutical companies, with direct settlements amounting to 23,337 million yuan for drugs and 3,283 million yuan for medical consumables [2] - An incentive mechanism has been put in place to encourage medical institutions to actively participate in procurement, with 741,000 yuan allocated for drug procurement savings and 19,000 yuan for consumables [2] Group 3: Accessibility Initiatives - Efforts to extend centralized procurement services to grassroots levels have been made, with 16 designated hospitals, 70 village clinics, and 88 designated pharmacies now providing access to procured drugs [3] - The initiative aims to enhance the accessibility of quality and affordable medications for the community, ensuring that essential drugs are available at local healthcare facilities [3]

Group 1: Housing Policy in Jinhua - The new housing provident fund policy in Jinhua allows young people to increase their maximum loan amount from 1.3 million to 1.69 million yuan, effective from December 1 [1] - The policy benefits young residents under 40 years old and new citizens who have not resided in Jinhua for three years, allowing them to withdraw funds based on actual rent payments and increasing loan limits for home purchases by 30% [1] - Additional measures include allowing family members to withdraw their provident fund to assist with loan repayments, enhancing support for homebuyers [1] Group 2: Pharmaceutical Supply in Linchuan - The Linchuan District has implemented a "three-in" initiative to make collective procurement drugs available in retail pharmacies, private medical institutions, and community health service centers, addressing issues of accessibility and affordability [2] - The initiative has seen 208 new medical institutions participate, expanding the range of procured drugs to 270 varieties, including common medications for chronic diseases [2] - The program has saved the public 8.2 million yuan in medication costs, with 4.92 million yuan saved from insurance funds and 3.28 million yuan from personal expenditures, demonstrating significant benefits to the community [2] Group 3: Shipping Development in Nanping - The successful maiden voyage of the "Minjiang 2" cargo ship marks a significant milestone in enhancing the shipping capacity of the Minjiang River, allowing for regular navigation of thousand-ton vessels [3] - The local transportation department has collaborated with the Water Mouth Power Station to improve shipping conditions, increasing the maximum navigable draft from 1.9 meters to 2.2 meters [4] - The port has seen a 38% year-on-year increase in cargo throughput, reaching 357,000 tons, and has implemented a multi-modal transport system to reduce logistics costs by 10% to 20% [4]